America is currently experiencing an opioid epidemic that has been killing its communities for decades. 2020 was the deadliest on record with more than 75.000 overdoses directly linked to opioids. Would a CBD-pill option? Many observers agree that this crisis was born in the early 1995s and was exacerbated in XNUMX by the licensing and mass marketing of Purdue Pharma's Oxycontin, an opiate-based pain reliever prescribed for pain relief.
Researchers across the spectrum have recently begun exploring how cannabis could be used to combat not only the pain suffered by patients, but also the country's over-reliance on prescription opioids.
One of these studies, conducted jointly in New York and Florida, USA by researchers at health care provider NYU Langone Health, assessed the efficacy, feasibility and overall safety of a new CBD product in the treatment of post-operative pain in patients who have recently undergone shoulder surgery. .
Further research into the use of CBD pill for shoulder pain
The product in the form of a CBD pill, ORAVEXX called, was tested in a phase 1/2 clinical trial and involved 99 participants between the ages of 18 and 75. All participants had just undergone surgery to repair the part of the shoulder known as their rotator cuff. Half of the group was treated with the CBD product, the other half was a control group that received a placebo. Their pain was measured using a standardized instrument called Visual Analog Scale (VAS).
Results presented at the annual meeting of the American Academy of Orthopedic Surgeons in Chicago, USA in 2022 showed that patients who received the CBD treatment experienced 23% less pain on the day of surgery than those in the control group.
On the first and second days of the patients' postoperative care, those who received CBD reported between 22% and 25% greater satisfaction with pain relief than those in the control group. Half of the patients in the CBD-receiving group received 50 mg of CBD and half received 25 mg. Half of the group that received 50 mg of CBD reported 'greater satisfaction with pain relief' than the half that received 25 mg.
Lead investigator of the trial, Michael J. Alaia, MD, an associate professor in the Department of Orthopedic Surgery at NYU Langone Health, said: “There is an urgent need for viable alternatives for pain management, and our study presents this form of CBD as a promising tool after arthroscopic rotator cuff repair. It could be a new, low-cost approach to delivering pain relief, and without the side effects of anti-inflammatory drugs like NSAIDs and addiction risks associated with opiates. In addition, CBD has the benefit of pain relief without the psychotropic effects associated with THC or marijuana.”
This study has produced positive results showing that cannabis, especially the cannabinoid CBD in the form of this CBD pill, can be a safe and useful tool in the fight against pain and society's over-reliance on prescription opioids. However, the cohort size in this clinical trial suggests that more research is needed.
While early academic research supports CBD as a pain treatment, non-GMP manufactured products with imprecise dosing, poor bioavailability, and difficult administration have made extensive empirical studies impractical.
ORAVEXX™ addresses these issues with a CBD pill and, when combined with our true placebo, allows researchers to accurately determine the safety and efficacy of CBD treatment through randomized controlled clinical trials.
Medical researchers have recognized the important promise of ORAVEXX™ and we are proud to support ongoing FDA-authorized, investigator-initiated clinical trials at leading US research institutions to continue the safety and effectiveness of ORAVEXX™ as an alternative treatment to opioid therapy evaluate for pain management.